These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 26702921)
1. A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro. Clewe O; Aulin L; Hu Y; Coates AR; Simonsson US J Antimicrob Chemother; 2016 Apr; 71(4):964-74. PubMed ID: 26702921 [TBL] [Abstract][Full Text] [Related]
2. The multistate tuberculosis pharmacometric model: a semi-mechanistic pharmacokinetic-pharmacodynamic model for studying drug effects in an acute tuberculosis mouse model. Chen C; Ortega F; Rullas J; Alameda L; Angulo-Barturen I; Ferrer S; Simonsson US J Pharmacokinet Pharmacodyn; 2017 Apr; 44(2):133-141. PubMed ID: 28205025 [TBL] [Abstract][Full Text] [Related]
3. Quantification of Natural Growth of Two Strains of Mycobacterium Marinum for Translational Antituberculosis Drug Development. Van Wijk RC; van der Sar AM; Krekels EHJ; Verboom T; Spaink HP; Simonsson USH; van der Graaf PH Clin Transl Sci; 2020 Nov; 13(6):1060-1064. PubMed ID: 32267997 [TBL] [Abstract][Full Text] [Related]
4. A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis. Clewe O; Faraj A; Hu Y; Coates ARM; Simonsson USH J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):421-430. PubMed ID: 32488575 [TBL] [Abstract][Full Text] [Related]
5. Assessing Pharmacodynamic Interactions in Mice Using the Multistate Tuberculosis Pharmacometric and General Pharmacodynamic Interaction Models. Chen C; Wicha SG; de Knegt GJ; Ortega F; Alameda L; Sousa V; de Steenwinkel JEM; Simonsson USH CPT Pharmacometrics Syst Pharmacol; 2017 Nov; 6(11):787-797. PubMed ID: 28657202 [TBL] [Abstract][Full Text] [Related]
6. Activity of Moxifloxacin against Louie A; Duncanson B; Myrick J; Maynard M; Nole J; Brown D; Schmidt S; Neely M; Scanga CA; Peloquin C; Drusano GL Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249693 [TBL] [Abstract][Full Text] [Related]
7. Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Paramasivan CN; Sulochana S; Kubendiran G; Venkatesan P; Mitchison DA Antimicrob Agents Chemother; 2005 Feb; 49(2):627-31. PubMed ID: 15673743 [TBL] [Abstract][Full Text] [Related]
8. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. Gumbo T; Louie A; Liu W; Ambrose PG; Bhavnani SM; Brown D; Drusano GL J Infect Dis; 2007 Jan; 195(2):194-201. PubMed ID: 17191164 [TBL] [Abstract][Full Text] [Related]
10. The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs. Bax HI; Bakker-Woudenberg IAJM; de Vogel CP; van der Meijden A; Verbon A; de Steenwinkel JEM Tuberculosis (Edinb); 2017 Jul; 105():80-85. PubMed ID: 28610791 [TBL] [Abstract][Full Text] [Related]
11. Application of the Multistate Tuberculosis Pharmacometric Model in Patients With Rifampicin-Treated Pulmonary Tuberculosis. Svensson RJ; Simonsson U CPT Pharmacometrics Syst Pharmacol; 2016 May; 5(5):264-73. PubMed ID: 27299939 [TBL] [Abstract][Full Text] [Related]
13. The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase. Mori G; Orena BS; Franch C; Mitchenall LA; Godbole AA; Rodrigues L; Aguilar-Pérez C; Zemanová J; Huszár S; Forbak M; Lane TR; Sabbah M; Deboosere N; Frita R; Vandeputte A; Hoffmann E; Russo R; Connell N; Veilleux C; Jha RK; Kumar P; Freundlich JS; Brodin P; Aínsa JA; Nagaraja V; Maxwell A; Mikušová K; Pasca MR; Ekins S Tuberculosis (Edinb); 2018 Sep; 112():98-109. PubMed ID: 30205975 [TBL] [Abstract][Full Text] [Related]
14. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis. Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646 [TBL] [Abstract][Full Text] [Related]
15. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Herbert D; Paramasivan CN; Venkatesan P; Kubendiran G; Prabhakar R; Mitchison DA Antimicrob Agents Chemother; 1996 Oct; 40(10):2296-9. PubMed ID: 8891133 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapeutic efficacy of thioridazine as an adjunct drug in a murine model of latent tuberculosis. Singh A; Sharma S Tuberculosis (Edinb); 2014 Dec; 94(6):695-700. PubMed ID: 25305001 [TBL] [Abstract][Full Text] [Related]
17. Effect of administration of moxifloxacin plus rifampin against Mycobacterium tuberculosis for 7 of 7 days versus 5 of 7 days in an in vitro pharmacodynamic system. Drusano GL; Sgambati N; Eichas A; Brown D; Kulawy R; Louie A mBio; 2011; 2(4):e00108-11. PubMed ID: 21750119 [TBL] [Abstract][Full Text] [Related]
18. The combination of rifampin plus moxifloxacin is synergistic for suppression of resistance but antagonistic for cell kill of Mycobacterium tuberculosis as determined in a hollow-fiber infection model. Drusano GL; Sgambati N; Eichas A; Brown DL; Kulawy R; Louie A mBio; 2010 Aug; 1(3):. PubMed ID: 20802826 [TBL] [Abstract][Full Text] [Related]
19. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Hu Y; Coates AR; Mitchison DA Int J Tuberc Lung Dis; 2006 Mar; 10(3):317-22. PubMed ID: 16562713 [TBL] [Abstract][Full Text] [Related]